Shares of Provention Bio soared Monday after the biopharmaceutical company agreed to be acquired by France’s Sanofi (SNY) for $25 a share, or about $2.9 billion. Provention Bio (ticker: PRVB), which f...
Tag: Provention
First Republic, Provention Bio, Roku, Illumina, Boeing, and More Market Movers
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...
Sanofi to buy Provention Bio in deal worth $2.9 billion
French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a deal with a...